Parenteral Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The parenteral packaging market is projected to expand from USD 21.53 billion in 2025 and USD 22.79 billion in 2026 to USD 32.05 billion by 2031, registering a CAGR of 7.06% between 2026 and 2031. This report is segmented by Product Type (Vials, Ampoules, Prefilled Syringes and Cartridges, and More), Material Type (Glass, Plastic and Polymer, and More), Packaging Type (Small-Volume Parenteral, Large-Volume Parenteral), End-User (Pharmaceutical Companies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Market Forecasts Provided in Terms of Value (USD).

Global Parenteral Packaging Market Trends and Insights

Rising Adoption of Biologics and Specialty Injectables

The parenteral packaging market is getting a direct lift from biologics, biosimilars, and specialty injectables because these products need validated primary containers and closures from the start. Each biosimilar developer must establish its own compatibility, extractables, leachables, and integrity profile for its own molecule and container combination, so packaging work rises faster than molecule counts alone would suggest. That dynamic gives the parenteral packaging market a deeper validation workload for every new launch, especially when the same therapy class expands across multiple sponsors and dosage forms. Stevanato Group reported that its GLP-1 packaging revenue grew by more than 50% in 2025, which shows how quickly one therapy class can change supplier demand. The same pattern supports steady demand for high-specification vials, cartridges, syringes, and elastomeric components across the parenteral packaging market.

Shift Toward Ready-to-Use and Presterilized Formats

The parenteral packaging market is moving toward ready-to-use and presterilized formats because fill-finish operators want fewer washing, depyrogenation, and sterilization steps on-site. That change matters most for CDMOs and multi-product plants, where shorter preparation time frees line capacity and lowers the risk of disruption during product changeovers. SCHOTT Pharma expanded vial production in Lebanon, Pennsylvania in June 2026 and added capacity for standard and sterile ready-to-use glass vials, including its adaptiQ and EVERIC lines. Gerresheimer also expanded its Wertheim site in 2025 with a new facility for sterile ready-to-fill vials under its EZ-fill Smart platform. As a result, the parenteral packaging market is treating ready-to-use formats less as a premium add-on and more as a practical way to protect throughput and supply reliability.

High Validation Burden for Container Closure Compatibility

The parenteral packaging market faces a real speed limit because any change in container material, coatings, siliconization, or closure composition can trigger new compatibility and integrity work. Under current guidance, this burden extends beyond first qualification and becomes part of routine change control across development and commercial supply. That slows switching between suppliers, formats, and sterilization approaches, even when a technical replacement appears straightforward. A 2026 paper in the Journal of Pharmaceutical Sciences noted that difficult-to-test parenteral products, including advanced biologic formats and novel container geometries, still lack standardized deterministic methods in some cases. This leaves the parenteral packaging market with longer qualification cycles and more hesitation around rapid adoption of new component systems.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Home-Care and Self-Administration Therapies
• Higher Demand for Container-Closure Integrity and Low-Extractables Systems
• Elevated Cost of High-Barrier and Sterile-Ready Formats

Segment Analysis

Vials held 41.24% of the parenteral packaging market share within product type in 2025, while prefilled syringes and cartridges are expected to advance at 8.10% CAGR through 2031. Vials remain deeply embedded in hospital production, CDMO fill-finish lines, and lyophilized or multi-dose applications, so their installed base still matters to the parenteral packaging market. Prefilled syringes and cartridges are gaining popularity faster because developers are converting more chronic therapies into single-use formats that simplify dosing, reduce handling, and fit home-care delivery models.

The parenteral packaging market is seeing this shift most clearly in GLP-1 treatments, subcutaneous monoclonal antibodies, and insulin-related programs, where device compatibility matters almost as much as container protection. The operational case for conversion is also becoming clearer across the parenteral packaging market. Prefilled formats reduce manual preparation steps and help lower product loss linked to withdrawal and dosing variability, which matters more when the active ingredient is costly.

Glass held 39.44% of the material segment in 2025, while the parenteral packaging market for plastic and polymer formats is projected to expand at 7.44% CAGR through 2031. Glass still anchors a large part of the parenteral packaging market because it has a long validation history, established pharmacopoeial acceptance, and broad familiarity across originators, generic producers, and outsourced manufacturers. At the same time, plastic and polymer formats are gaining popularity because sensitive biologics can react poorly to some glass surface issues, and developers want lower fragmentation risk in transport and use.

The parenteral packaging market is not shifting away from glass in a uniform way. PVC still has a role in large-volume parenteral bags, while polyolefin formats such as polypropylene and polyethylene are drawing interest where recyclability and drug compatibility support the case for substitution. Material choice now depends less on broad category preference and more on the interplay between drug chemistry, particulate risk, sterilization route, and final delivery device.

Complete Report Scope:

• By Product Type
  • Vials
  • Ampoules
  • Prefilled Syringes and Cartridges
  • Bags and Bottles
  • Ready-to-Mix Systems
• By Material Type
  • Glass
  • Plastic and Polymer
  • Poly Vinyl Chloride
  • Polyolefin
• By Packaging Type
  • Small-Volume Parenteral
  • Large-Volume Parenteral
• By End-User
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • CDMOs / CPOs
  • Hospitals & Healthcare Facilities
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 44.53% share of the parenteral packaging market in 2025, which kept it in the leading regional position. The region benefits from a dense concentration of biologics manufacturing, fill-finish operations, and regulatory oversight that gives container validation and integrity testing a central role in product approval. The parenteral packaging market in the United States is also supported by domestic supply chain investment, especially in ready-to-use vial capacity and advanced sterile systems. SCHOTT Pharma inaugurated expanded production in Lebanon, Pennsylvania, in June 2026 and said the investment added new standard and sterile ready-to-use glass vial lines while more than tripling local capacity for higher-value solutions. PCI Pharma Services also announced a broader sterile fill-finish expansion program in April 2026 that included a new high-speed isolator filling line in San Diego for ready-to-use prefilled syringes and cartridges.

Europe remains the second-largest regional block in the parenteral packaging market because it has a dense base of pharmaceutical glass and polymer container specialists. Regional suppliers continue to serve both local fill-finish operations and global export demand, which keeps Europe central to primary container and component supply. Gerresheimer expanded its Wertheim site in 2025 to strengthen sterile ready-to-fill vial output, which reflects steady demand for premium pharmaceutical packaging in the region. European producers are also trying to lower the carbon footprint of packaging operations without disrupting validated material systems, which supports investment in cleaner production rather than abrupt material substitution.

Asia-Pacific is projected to grow at 10.33% CAGR through 2031, making it the fastest-growing region in the parenteral packaging market. China remains an important demand center for biologics packaging, and West Pharmaceutical Services used CPHI and PMEC China 2026 to launch its integrated prefillable syringe system for that ecosystem. India is building both local demand and manufacturing depth, with Amcor expanding healthcare packaging production in Karnataka in June 2026 and Nipro having added glass cartridge capacity at Pune in 2025 for wider regional use. South America, the Middle East, and Africa remain smaller parts of the parenteral packaging market, with growth tied more closely to healthcare infrastructure spending and local pharmaceutical manufacturing build-out than to large global supply leadership.

List of Companies Covered in this Report:

• Amcor plc
• AptarGroup, Inc.
• Baxter
• Beckton Dickinson
• Berry Global, Inc.
• Catalent
• Corning
• Daikyo Seiko, Ltd.
• Gerresheimer
• Nipro
• Owen-Illinois, Inc.
• Piramal Glass Private Limited
• SCHOTT
• SGD Pharma
• Shandong Pharmaceutical Glass Co., Ltd.
• Stevanato Group
• Terumo
• West Pharmaceutical Services
• WestRock Company
• Ypsomed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support